Genmab — August 2017
-
Det havde faktisk nogle rigtig gode egenskaber men Genmab har stillet det i bero - eller puttet det i mølposen. De skriver dog på hjemmesiden at det er til rådighed mod licensbetaling såfremt nogen vil tænke det ind i et target. Men det er jo bar "skriv" - så det !
-
Her skriver de så som kommentar til tidligere trials: According to the study protocol, patients receiving zalutumumab were not permitted to receive treatment with methotrexate, while it was permitted and used to treat 78% of patients in the BSC group. Recent data suggest that methotrexate may be an active treatment in head and neck cancer, which was unknown at the time the zalutumumab study was designed.
-
Interview med Shaji Kumar, som runder det nyeste på MM-scenen - incl CAR-T. Fra i mandags http://www.targetedonc.com/news/expert-shares-promising-findings-for-longterm-ixazomib-maintenance-in-newly-diagnosed-myeloma
-
Paul Richardson har været til møde i British Society for Haematology, hvor han skamroste dara. Ikke noget nyt. https://www.youtube.com/watch?v=GaCyl7TPzOg
-
God morgen .

-
Tak Bulder.

-
Tak Bulder han er skarp at høre påog der er flere fra marts konferencen. Richardson her om hele landskabet: https://www.youtube.com/watch?v=fRASFgrMAik
-
-
Enskilda er i gang igen. De sælger ned i en lavere kurs i det sekund spreadet giver mulighed for det
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
